Menu Search
Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Actions
Health CareHealth Care Providers
  • Price (GBX)4.25
  • Today's Change0.00 / 0.00%
  • Shares traded130.05k
  • 1 Year change+32.81%
  • Beta0.4006
Data delayed at least 20 minutes, as of Nov 25 2024 16:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Fusion Antibodies PLC had revenues fall -60.84% from 2.90m to 1.14m, though the company grew net income from a loss of 2.60m to a smaller loss of 2.23m.
Gross margin20.20%
Net profit margin-90.29%
Operating margin-92.29%
Return on assets-90.74%
Return on equity-129.49%
Return on investment-125.54%
More ▼

Cash flow in GBPView more

In 2024, Fusion Antibodies PLC increased its cash reserves by 514.87%, or 1.00m. Cash Flow from Financing totalled 2.77m or 243.84% of revenues. In addition the company used 1.77m for operations while cash from investing totalled 1.00k.
Cash flow per share-0.0184
Price/Cash flow per share--
Book value per share0.0111
Tangible book value per share0.0111
More ▼

Balance sheet in GBPView more

Fusion Antibodies PLC appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio3.25
Quick ratio2.73
Total debt/total equity0.0302
Total debt/total capital0.0293
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.